Eli Lilly India is placing increasing importance on the country’s biotechnology, research and pharmaceutical ecosystem. The company sees opportunities in India across innovation, manufacturing, research collaborations and potential biotech partnerships, while continuing to expand its global focus on obesity and cardiometabolic medicines. Eli Lilly CEO David A. Ricks recently highlighted India’s scientific talent and manufacturing capabilities, while also pointing to gaps in biotech funding and research infrastructure. The Economic Times
Quick Summary
Eli Lilly sees strong potential in the India biotech ecosystem because of its scientific talent, research capabilities and manufacturing base. The company is exploring opportunities in manufacturing and potential biotech partnerships while expanding its obesity-medicine pipeline. Lilly also has a significant India presence, including operations in Bengaluru, Gurugram and Hyderabad. Lilly
Overview of Eli Lilly’s India Strategy
Eli Lilly is one of the world’s major pharmaceutical companies and has built a strong position in diabetes, obesity and cardiometabolic healthcare.
According to an October 2026 interview with Lilly CEO David A. Ricks, the company considers India’s biotech ecosystem promising for future opportunities, including manufacturing and potential acquisitions or partnerships. The Economic Times
India is also becoming more important to Lilly’s global operations. The company says it has maintained a presence in India for more than three decades and operates through entities in Gurugram, Bengaluru and Hyderabad. Lilly
Key Highlights
| Area | Key Point |
|---|---|
| Company | Eli Lilly and Company |
| CEO | David A. Ricks |
| India Focus | Biotechnology, research, manufacturing and partnerships |
| Major Therapeutic Areas | Obesity, diabetes and cardiometabolic health |
| India Presence | Gurugram, Bengaluru and Hyderabad |
| Research Hub | Bengaluru |
| Major Obesity Medicines/Pipeline | Mounjaro, Foundayo and investigational retatrutide |
| Key Challenge in India | Biotech funding and research infrastructure |
Eli Lilly’s Growth in the Global Pharmaceutical Market
Eli Lilly has experienced exceptional growth as demand for innovative obesity and diabetes medicines has increased.
The company’s market capitalisation has risen dramatically over the past several years. The Economic Times reported in October 2026 that Lilly had crossed the $1 trillion market-capitalisation level, with its growth strongly associated with demand for anti-obesity medicines and products such as Mounjaro. The Economic Times
The company’s growing obesity portfolio has become a major part of its global growth strategy.
Eli Lilly’s Focus on Obesity Medicines
Obesity treatment is one of Lilly’s most important areas of research and development.
Its portfolio includes tirzepatide, marketed as Mounjaro, while the company is also advancing newer medicines and combinations.
Retatrutide
Retatrutide is an investigational medicine that activates GIP, GLP-1 and glucagon receptors. Lilly reported positive Phase 3 results across multiple studies in 2026. Lilly
However, retatrutide is not yet available for public use and remains an investigational medicine being studied in clinical trials. Lilly
Foundayo (Orforglipron)
Foundayo (orforglipron) is Lilly’s oral GLP-1 medicine. Lilly has reported positive results from its Phase 3 development programme, including studies evaluating diabetes, weight and cardiometabolic outcomes. Lilly
EloraTZP
Lilly is also developing EloraTZP, a combination of eloralintide and tirzepatide.
In September 2026, Lilly reported positive Phase 2b results and said it plans to initiate Phase 3 trials in Q4 2026. Eli Lilly and Company
India Emerges as an Important Market for Lilly
India represents an important opportunity for Lilly because of its large patient population, expanding healthcare needs and growing pharmaceutical capabilities.
The company has stated that India offers significant potential in areas such as:
- Scientific research
- Biotechnology
- Manufacturing
- Clinical research
- Healthcare innovation
- Strategic partnerships
Lilly’s India operations have also become part of its wider global network.
According to the company’s India profile, Lilly has been present in the country for more than 30 years and considers India an important part of its global footprint. Lilly
Why India’s Biotech Ecosystem Matters
Lilly CEO David Ricks highlighted several strengths of India’s biotech ecosystem.
Major Strengths
1. Scientific Talent
India has a large pool of scientists and technical professionals supporting pharmaceutical and biotechnology research.
2. Research Capabilities
The country has developed capabilities across pharmaceutical research, laboratory sciences and clinical development.
3. Manufacturing Expertise
India is already an important global pharmaceutical manufacturing hub, creating opportunities for additional collaborations.
4. Growing Healthcare Market
Increasing healthcare demand creates opportunities for innovative medicines and healthcare technologies.
Challenges for India’s Biotech Sector
Despite its strengths, India’s biotech ecosystem still faces challenges.
According to Ricks, areas such as venture funding, clinical-trial infrastructure, animal-research facilities and supporting laboratory infrastructure need further development. China Tech News
| Strengths | Challenges |
|---|---|
| Scientific talent | Limited biotech funding |
| Research capabilities | Venture funding environment |
| Manufacturing expertise | Clinical-trial infrastructure |
| Large healthcare market | Research-support ecosystem |
| Pharmaceutical experience | Laboratory and experimental infrastructure |
Eli Lilly’s Research Presence in India
Lilly has established a significant operational and research presence in India.
The company’s Bengaluru site was established as a global capability hub in 2016 and is described by Lilly as its largest site outside the United States. Lilly
Lilly’s India operations support areas connected with its global activities, while the company also works with manufacturing partners in the country. Lilly
AI and the Future of Drug Discovery
Artificial intelligence is becoming an increasingly important technology in pharmaceutical research.
AI can help researchers analyse large datasets, identify patterns and improve the efficiency of experimental and drug-development workflows.
For pharmaceutical companies such as Lilly, AI is being explored as a tool to support scientists rather than simply replace laboratory research.
The potential applications include:
- Analysing experimental data
- Predicting research outcomes
- Identifying potentially problematic candidates
- Supporting decision-making
- Improving research efficiency
- Accelerating parts of the drug-development process
Eli Lilly and Future Biotech Partnerships in India
India’s growing biotechnology sector could create opportunities for pharmaceutical companies looking for research, manufacturing and strategic partnerships.
Lilly’s CEO has indicated that the company continues to explore possibilities in India, including manufacturing and acquisitions. The Economic Times
However, the extent and timing of any future acquisition or partnership opportunities are not mentioned in the official company sources reviewed for this article.
Expanding Access to Obesity Treatments
Access and affordability remain important challenges for newer obesity medicines.
As obesity treatments become more widely used, pharmaceutical companies face the challenge of expanding access across countries and different income groups.
India is particularly important in this discussion because it combines a large population, growing healthcare demand and a developing market for newer obesity treatments.
What Eli Lilly’s India Focus Means for the Pharma Industry
Lilly’s increasing interest in India highlights several broader trends in the pharmaceutical industry.
1. More Global Pharma Interest in India
India is increasingly important not only as a pharmaceutical manufacturing centre but also as a research and innovation destination.
2. Growth of Biotech Partnerships
Indian biotech companies may have opportunities to work with multinational pharmaceutical companies in research, development and manufacturing.
3. Increasing Importance of Obesity Research
The rapid development of obesity medicines is changing the global pharmaceutical market and creating new research opportunities.
4. AI Will Support Pharmaceutical Research
AI is expected to become increasingly useful in areas such as drug discovery, data analysis and research optimisation.
Opportunities for India’s Pharma and Biotech Sector
If India continues to strengthen its biotech infrastructure, the country could attract greater investment and international collaboration.
Potential areas of opportunity include:
- Pharmaceutical R&D
- Biotechnology startups
- Clinical research
- Contract manufacturing
- Drug discovery
- AI-enabled healthcare research
- Academic-industry collaboration
- Global pharmaceutical partnerships
Why This Update Matters for Pharmacy Students
For B.Pharm, M.Pharm, Pharm.D and other pharmacy students, developments in global pharmaceutical companies can provide useful insights into emerging career and research areas.
The growing focus on obesity medicines, biotechnology, clinical research, manufacturing and AI-enabled drug discovery highlights the increasing importance of interdisciplinary skills in the pharmaceutical industry.
Students interested in pharmaceutical research, pharmacovigilance, clinical research, biotechnology, drug discovery and pharma industry careers can particularly benefit from following these developments.
Frequently Asked Questions
1. Why is Eli Lilly interested in India’s biotech ecosystem?
Eli Lilly sees potential in India’s scientific talent, research capabilities and manufacturing base and is exploring opportunities involving manufacturing and potential biotech partnerships or acquisitions. The Economic Times
2. What is Eli Lilly’s major focus in the obesity medicine market?
Obesity and cardiometabolic health are major areas of Lilly’s innovation strategy, with medicines and investigational programmes including tirzepatide, orforglipron and retatrutide. Eli Lilly and Company
3. What is retatrutide?
Retatrutide is an investigational once-weekly medicine that activates GIP, GLP-1 and glucagon receptors. It is still being evaluated in clinical trials and is not yet available for public use. Lilly
4. What is Foundayo?
Foundayo is the brand name for orforglipron, Lilly’s oral GLP-1 medicine. Lilly has reported Phase 3 results evaluating its effects on blood glucose, weight and cardiometabolic outcomes. Eli Lilly and Company
5. Does Eli Lilly have operations in India?
Yes. Lilly says it has been present in India for more than 30 years and operates through entities in Gurugram, Bengaluru and Hyderabad. Lilly
6. Where is Eli Lilly’s major global capability hub in India?
Lilly established its global capability hub in Bengaluru in 2016. The company describes the Bengaluru site as its largest site outside the United States. Lilly
7. What challenges does India’s biotech ecosystem face?
According to Lilly’s CEO, challenges include the funding environment, venture capital, clinical-trial infrastructure, animal-research facilities and supporting laboratory infrastructure. China Tech News
8. How can AI help pharmaceutical research?
AI can support pharmaceutical research by analysing large datasets, identifying patterns, predicting experimental outcomes and improving the efficiency of parts of the drug-development process.
Conclusion
Eli Lilly’s growing focus on India highlights the country’s increasing importance in the global pharmaceutical and biotechnology ecosystem.
India offers a strong combination of scientific talent, pharmaceutical manufacturing expertise, research capabilities and a large healthcare market. At the same time, improving biotech funding, clinical research infrastructure and innovation support will be important for unlocking the sector’s full potential.
For India’s pharma and biotech industry, greater collaboration with global companies such as Lilly could create opportunities across research, manufacturing, drug discovery, biotechnology and healthcare innovation.
As Lilly continues to advance medicines in obesity and cardiometabolic health and expand its global research capabilities, India’s role in the company’s wider ecosystem could become increasingly important.
Recommended Products
